Mineralys Therapeutics, Inc. financial data

Symbol
MLYS on Nasdaq
Location
150 N. Radnor Chester Road, Suite F200, Radnor, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.22K % -53.2%
Return On Equity -68 % -157%
Return On Assets -62.4 % -144%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.8M shares
Common Stock, Shares, Outstanding 49.8M shares +21.1%
Entity Public Float 400M USD +66.6%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 48.5M shares +34.1%
Weighted Average Number of Shares Outstanding, Diluted 48.5M shares +34.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 169M USD +140%
General and Administrative Expense 23.8M USD +66.6%
Operating Income (Loss) -192M USD -127%
Nonoperating Income (Expense) 14.6M USD +14.4%
Net Income (Loss) Attributable to Parent -178M USD -147%
Earnings Per Share, Basic -3.66 USD/shares -83.9%
Earnings Per Share, Diluted -3.66 USD/shares -83.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 114M USD +131%
Assets, Current 205M USD -17.6%
Property, Plant and Equipment, Net 53K USD
Other Assets, Noncurrent 499K USD +878%
Assets 206M USD -18.2%
Accounts Payable, Current 479K USD -20.3%
Accrued Liabilities, Current 14.2M USD +43.4%
Liabilities, Current 14.6M USD +39.7%
Retained Earnings (Accumulated Deficit) -303M USD -143%
Stockholders' Equity Attributable to Parent 191M USD -20.7%
Liabilities and Equity 206M USD -18.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.1M USD -49.8%
Net Cash Provided by (Used in) Financing Activities 116M USD -42.9%
Net Cash Provided by (Used in) Investing Activities -56M USD +60.1%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 49.8M shares +21.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 41.1M USD -18.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 114M USD +131%
Deferred Tax Assets, Valuation Allowance 79.9M USD +154%
Deferred Tax Assets, Gross 79.9M USD +154%
Deferred Tax Assets, Operating Loss Carryforwards 15.6M USD +97.5%
Unrecognized Tax Benefits 4.51M USD +319%
Additional Paid in Capital 494M USD +35%
Depreciation, Depletion and Amortization 8K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 11.3M USD +124%